Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Structural characterization of CD40L-Tn3 molecule and interactions.
  • Fig. S2. Mouse surrogate Tn3 shows potent neutralizing activity in vivo in response to immunization.
  • Fig. S3. Study design for phase 1a study to evaluate safety of VIB4920.
  • Fig. S4. Phase 1b study design to evaluate VIB4920 in patients with RA.
  • Fig. S5. Dose-dependent reduction in DAS28-CRP and RF autoantibodies in RA in response to VIB4920.
  • Fig. S6. Impact of VIB4920 on tender/swollen joint counts and CRP in phase 1b study in patients with RA.
  • Table S1. Fusion with serum albumin greatly improves half-life of Tn3 molecule.
  • Table S2. VIB4920 demonstrates a good safety profile in healthy volunteers.
  • Table S3. VIB4920 demonstrates an acceptable safety profile in patients with RA.
  • Table S4. DAS28 categories at day 85.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: